ARK Reports 4.91% Tempus AI Position — Says It Is Not Seeking Control
Catherine D. Wood is a co-reporting person for the same 8,607,836-share position.
ARK Investment Management reported a 4.91% position in Tempus AI, which combines diagnostic testing with patient clinical data, in a passive ownership disclosure filed Friday. ARK said the investment belongs to its ordinary business activities and is not intended to change or influence the company's control.
One position, two reporting persons
The position comprises 8,607,836 common shares on the disclosure's beneficial-ownership basis. The ownership event is dated October 31, 2026; Friday is the filing date.
Catherine D. Wood is a co-reporting person for that same position, rather than a separate holding to add to ARK's total. Wood, identified as chief executive officer and chief investment officer, agreed with ARK to file jointly.
Voting authority differs between the reporting persons. ARK has sole voting authority over 8,161,270 shares and shared authority over 124,106. Wood has shared voting authority over 8,285,376 shares and no sole voting authority.
ARK also reports sole authority to dispose of 8,607,836 shares, while Wood reports shared disposal authority over the same number.
Cancer testing and clinical data
Tempus sells genomic sequencing and pathology tests to healthcare providers, life sciences companies and researchers. Its data and applications business licenses de-identified information and supplies analytics, clinical-trial support and algorithm-based diagnostics to pharmaceutical and biotechnology companies through Insights, Trials, Next and Algos.
The company's operations include five testing laboratories and about 700 direct data connections across roughly 5,000 hospitals. Its provider network covers more than 55% of U.S. oncologists, and its database contained more than 8.6 million de-identified patient records as of December 31, 2025.
Tempus AI shares rose about 7% to $75.69 in Friday trading. The company's market capitalization stood at $12.8 billion in Friday trading.
ARK's stated purpose is ordinary-course investing, not an effort to influence control of Tempus AI.
Sources
- SCHEDULE 13G/A — ARK Investment Management LLC re: Tempus AI, Inc. (TEM) — SEC EDGAR
- SCHEDULE 13G/A Exhibit 1 — EXHIBIT 1 — SEC EDGAR
- Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3 — Yahoo Finance
